ILMN - Illumina, Inc.
NEXT EARNINGS:
May 14, 2026
EPS Est: $1.09
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$144.56
DETAILS
HIGH:
$170.00
LOW:
$110.00
MEDIAN:
$150.00
CONSENSUS:
$144.56
UPSIDE:
17.62%
Market Cap:
18.79B
Volume:
2,321,896
Avg Volume:
1,959,526
52 Week Range:
68.7-155.53
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Beta:
1.45
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
8,970
IPO Date:
2000-07-28
EPS (TTM):
5.47
P/E Ratio:
23.61
Revenue (TTM):
4.34B
Total Assets:
6.64B
Total Debt:
2.55B
Cash & Equiv:
1.42B
Rev Growth (5Y):
3.4%
EPS Growth (5Y):
-3.6%
FCF Growth (5Y):
1.7%
ROCE:
23.4%
Debt/Equity:
0.94
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-05 | $1.35 | $1.26 | +7.1% | $1.2B | $1.1B | +8.0% |
| 2025-10-30 | $1.34 | $1.17 | +14.5% | $1.1B | $1.1B | +1.6% |
| 2025-07-31 | $1.19 | $1.02 | +16.7% | $1.1B | $1.1B | -0.6% |
| 2025-05-08 | $0.97 | $0.94 | +3.2% | $1.0B | $1.0B | +1.5% |
| 2025-02-06 | $0.86 | $0.92 | -6.5% | $1.1B | $1.1B | +3.0% |
| 2024-11-04 | $1.14 | $0.88 | +29.7% | $1.1B | $1.1B | 0.0% |
| 2024-08-06 | $0.36 | $0.11 | +228.5% | $1.1B | $1.1B | +1.7% |
| 2024-05-02 | $0.09 | $0.04 | +106.4% | $1.1B | $1.1B | +2.4% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.34B | 4.37B | 4.50B | 4.58B | 4.53B | 3.24B | 3.54B | 3.33B | 2.75B | 2.40B | 2.22B | 1.86B |
| Net Income | 850.00M | (1.22B) | (1.16B) | (4.40B) | 762.00M | 656.00M | 1.00B | 826.00M | 726.00M | 462.65M | 461.56M | 353.35M |
| EPS | 5.47 | -7.69 | -7.35 | -28.05 | 5.08 | 4.46 | 6.82 | 5.62 | 4.97 | 3.15 | 3.18 | 2.61 |
| Total Assets | 6.64B | 6.30B | 10.11B | 12.25B | 15.22B | 7.58B | 7.32B | 6.96B | 5.26B | 4.28B | 3.69B | 3.34B |
| Total Debt | 2.55B | 2.62B | 2.26B | 3.56B | 2.54B | 1.91B | 1.88B | 2.00B | 1.19B | 1.05B | 1.09B | 1.29B |
| Cash & Equivalents | 1.42B | 1.13B | 1.05B | 2.01B | 1.23B | 1.81B | 2.04B | 1.14B | 1.23B | 734.52M | 768.77M | 636.15M |
| Operating Cash Flow | 1.08B | 837.00M | 478.00M | 392.00M | 545.00M | 1.08B | 1.05B | 1.14B | 875.00M | 687.24M | 659.60M | 501.27M |
| Free Cash Flow | 931.00M | 709.00M | 282.00M | 106.00M | 337.00M | 891.00M | 842.00M | 846.00M | 563.00M | 415.86M | 516.35M | 359.06M |
| FCF per Share | 6.08 | 4.46 | 1.78 | 0.68 | 2.25 | 6.06 | 5.73 | 5.76 | 3.86 | 2.83 | 3.56 | 2.65 |
| Book Value | 2.72B | 2.37B | 5.75B | 6.60B | 10.74B | 4.69B | 4.61B | 3.85B | 2.84B | 2.27B | 1.85B | 1.46B |
| Cash & ST Investments | 1.63B | 1.22B | 1.05B | 2.04B | 1.34B | 3.47B | 3.41B | 3.51B | 2.15B | 1.56B | 1.39B | 1.34B |
| ROC Equity | 0.31 | -0.52 | -0.20 | -0.67 | 0.07 | 0.14 | 0.22 | 0.21 | 0.26 | 0.20 | 0.25 | 0.24 |